Tetrous, a Los Angeles, CA-based startup focused on bone-to-tendon healing following orthopedic surgery, closed its Series A financing round, raising a total of $6.5M.
Backers were not disclosed.
The company intends to use the funds to increase its market penetration, develop further clinical data showing the improvement in outcomes for patients, and expand surgical applications of its patented technology, including for hip, knee, ankle and elbow procedures with existing and new product offerings.
Led by CEO Simon Berry, Tetrous utilizes advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. The company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 150,000 implants in spine applications.
Tetrous enjoys IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company.
FinSMEs
10/03/2025